Press
News, study background and media resources for Melonga
Melonga is a CE-marked digital therapeutic for premature ejaculation, developed by Prognoix Health B.V. It is the subject of CLIMACS, a randomised controlled trial conducted with the Department of Urology at Philipps-Universität Marburg, presented at the EAU Congress 2026 in London.
+4.4
Mean change in PEP score, vs. +0.03 in the control group (p<0.001)
61 → 125s
Average IELT before and after the 12-week programme
80
Men randomised 1:1 in the CLIMACS trial; 66 complete datasets analysed
About the CLIMACS study
CLIMACS is a randomised, unblinded controlled trial evaluating Melonga for the treatment of premature ejaculation (EP), led by PD Dr. Christer Groeben. Eighty men were randomised 1:1 to twelve weeks of the Melonga programme or a waitlist control; the control group was subsequently offered access to the app. Sixty-six participants submitted complete questionnaires for analysis. The trial is registered with the German Clinical Trials Register (DRKS00032774) and was sponsored by Prognoix Health B.V.
Primary endpoint (PEP score): mean change of +4.4 in the intervention group vs. +0.03 in the control group (p<0.001).
IELT: mean between-group difference of +75.7 seconds vs. +0.5 seconds in the control group (p=0.001); intervention-group IELT rose from 61 to 125 seconds on average.
SQoL-M (sexuality-related quality of life): +13.4 points in the intervention group vs. −0.1 in the control group (p=0.009).
PEDT: at 12 weeks, 24.2% of analysed participants (16 of 66) scored ≤8 on the Premature Ejaculation Diagnostic Tool, indicating a low likelihood of clinically significant EP.
Results were presented at the EAU Congress 2026 in London (13–16 March) and at the DGU Congress 2025. A peer-reviewed full publication of the final results is not yet available and is in preparation. Melonga is a CE-marked Class I medical device under Regulation (EU) 2017/745; it is intended to support self-management of premature ejaculation and does not replace medical diagnosis or treatment.
In the news
Deutsches Ärzteblatt — 9 June 2026
Smartphone-App erfolgreich gegen vorzeitigen Samenerguss eingesetzt
The journal of the German Medical Association reports on the CLIMACS results presented at EAU 2026, noting that roughly a quarter of participants no longer met the criteria for the condition after the twelve-week programme.
Urologische Stiftung Gesundheit (DGU) — 28 August 2026
Vorzeitiger Samenerguss: Studie zeigt Wirksamkeit von Handy-App
An in-depth interview with study lead PD Dr. Christer Groeben on the CLIMACS design, results and what they mean for patients and clinicians, published by the German Society of Urology’s patient foundation.
mgo medizin — 22 June 2026
App statt Pille: Smartphone-Anwendung hilft Männern, länger durchzuhalten
Trade coverage for physicians summarising the CLIMACS design and outcomes, sourced to the EAU’s congress press release, with a clear note that the final results are not yet peer-reviewed.
ärztenachrichtendienst (aend.de) — 2026
Smartphone-Training gegen vorzeitigen Samenerguss
Physician-focused news coverage of the CLIMACS results presented at EAU 2026. Full article requires an aend.de login.
futurezone.at — 17 March 2026
Neue App soll Männern helfen, im Bett länger durchzuhalten
Austrian consumer-tech coverage of the CLIMACS findings, including comment from Prognoix co-founder Abhinav Jain on why so few men seek help: “90 Prozent der Betroffenen holen sich keine ärztliche Hilfe.”
heute.at — 17 March 2026
Peinliches Problem vieler Männer – neue App soll helfen
Austrian consumer coverage of the EAU 2026 presentation, aimed at a general audience.
Media kit
Logos, product screenshots and approved imagery for editorial use are available on our media kit page.
Media contact
For interview requests, additional data or comment: hello@melonga.com
Prognoix Health B.V., Oxfordlaan 55, 6229 EV Maastricht, Netherlands
Melonga is a CE-marked Class I medical device under Regulation (EU) 2017/745, intended to support self-management of premature ejaculation. It does not replace medical diagnosis or treatment. CLIMACS results reported above are from data presented at the EAU Congress 2026 and the DGU Congress 2025; a peer-reviewed full publication is pending. Prognoix Health B.V., Oxfordlaan 55, 6229 EV Maastricht, Netherlands.